Terms: = Lymphoma AND NUP214, ENSG00000126883, 8021, MGC104525, D9S46E, RP11-544A12_7, N214, CAIN, P35658, CAN AND Clinical Outcome
443 results:
1. Biological signatures of the International Prognostic Index in diffuse large B-cell lymphoma.
Wang Y; Shi Q; Shi ZY; Tian S; Zhang MC; Shen R; Fu D; Dong L; Yi HM; Ouyang BS; Mu RJ; Cheng S; Wang L; Xu PP; Zhao WL
Blood Adv; 2024 Apr; 8(7):1587-1599. PubMed ID: 38170757
[TBL] [Abstract] [Full Text] [Related]
2. Evaluation of the cachexia index using a bioelectrical impedance analysis in elderly patients with non-Hodgkin's lymphoma: A single-center prospective study.
Okubo S; Shinmura K; Kadota S; Nakayasu M; Kurosawa S; Nakayama H; Sakurai A; Ito C; Aisa Y; Nakazato T
Ann Hematol; 2024 Mar; 103(3):823-831. PubMed ID: 38010408
[TBL] [Abstract] [Full Text] [Related]
3. Suspected primary bone marrow T-cell lymphoid neoplasia causing paraneoplastic hypercalcemia in 11 dogs (2014-2021).
Portanova A; Rout ED; Avery AC; Viall AK
J Am Vet Med Assoc; 2024 Mar; 262(3):1-9. PubMed ID: 37922707
[TBL] [Abstract] [Full Text] [Related]
4. Whole exome germline sequencing in early-onset prostate cancer patients: Genomic findings and clinical outcomes.
Siegelmann-Danieli N; Neiman V; Bareket-Samish A; Berger R; Peretz A; Alapi H; Tsur E; Patalon T; Beller D; Rimler G; Chodick G; Shohat M
Prostate; 2024 Jan; 84(1):39-46. PubMed ID: 37842866
[TBL] [Abstract] [Full Text] [Related]
5. Adult T-cell leukemia/lymphoma in HTLV-1 non-endemic regions.
de Mendoza C; Rando A; Miró E; Pena MJ; Rodríguez-Avial I; Ortega D; González-Praetorius A; Reina G; Pintos I; Pozuelo MJ; Soriano V;
J Clin Virol; 2023 Oct; 167():105578. PubMed ID: 37660433
[TBL] [Abstract] [Full Text] [Related]
6. MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and
Rodrigues JM; Hollander P; Schmidt L; Gkika E; Razmara M; Kumar D; Geisler C; Grønbæk K; Eskelund CW; Räty R; Kolstad A; Sundström C; Glimelius I; Porwit A; Jerkeman M; Ek S
Haematologica; 2024 Apr; 109(4):1171-1183. PubMed ID: 37646663
[TBL] [Abstract] [Full Text] [Related]
7. Early changes in soluble intracellular adhesion molecule-1 as prognostic biomarkers to immune checkpoint inhibitor.
Ji D; Jiang S; Zhang Q; Wang YK; Zhang J; Shen W; Li W; Liu R; Wang J; Mavis C; Gu JJ; Hu X
Clin Transl Sci; 2023 Aug; 16(8):1396-1407. PubMed ID: 37317057
[TBL] [Abstract] [Full Text] [Related]
8. clinical Analysis of Pediatric T-Cell Acute Lymphoblastic Leukemia Using the MRD-Oriented Strategy System.
Xue YJ; Wang Y; Lu AD; Jia YP; Zuo YX; Ding MM; Zeng HM; Zhang LP
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):477-483. PubMed ID: 37080879
[TBL] [Abstract] [Full Text] [Related]
9. Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study.
Lazzarotto D; Tanasi I; Vitale A; Piccini M; Dargenio M; Giglio F; Forghieri F; Fracchiolla N; Cerrano M; Todisco E; Papayannidis C; Leoncin M; Defina M; Guolo F; Pasciolla C; Delia M; Chiusolo P; Mulè A; Candoni A; Bonifacio M; Pizzolo G; Foà R
Ann Hematol; 2023 May; 102(5):1099-1109. PubMed ID: 36959485
[TBL] [Abstract] [Full Text] [Related]
10. [The impact of donor-to-recipient gender compatibility on outcomes of haploid hematopoietic stem cell transplantation in patients with hematological malignancies].
Hu SS; Wu YB; Zhu PP; Shi JM; Yu J; Zhao YM; Lai XY; Liu LZ; Fu HR; Huang H; Luo Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):992-1002. PubMed ID: 36709104
[No Abstract] [Full Text] [Related]
11. The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.
Kiamanesh Z; Ayati N; Sadeghi R; Hawkes E; Lee ST; Scott AM
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4661-4676. PubMed ID: 35932329
[TBL] [Abstract] [Full Text] [Related]
12. Preliminary Report of the Academic CAR-T (ISIKOK-19) Cell clinical Trial in Turkey: Characterization of Product and outcomes of clinical Application.
Erdoğan E; Yalçın K; Hemşinlioğlu C; Sezgin A; Seyis U; Kançağı DD; Taştan C; Yurtsever B; Turan RD; Çakırsoy D; Abanuz S; Sır Karakuş G; Elek M; Bekoz HS; Gemici Aİ; Sargın D; Arat M; Ferhanoğlu B; Pekgüç E; Örnek S; Büyüktaş D; Birgen N; Ratip S; Ovalı E
Turk J Haematol; 2022 Aug; 39(3):206-210. PubMed ID: 35848614
[TBL] [Abstract] [Full Text] [Related]
13. Milestones in Hematology and Oncology: From Fatal to Curable Disease.
Amzai G; Karanfilski O
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2022 Jul; 43(2):145-157. PubMed ID: 35843924
[No Abstract] [Full Text] [Related]
14. clinical outcomes of Scanning Carbon-ion Radiotherapy for Soft Tissue Sarcoma of the Extremities.
Takakusagi Y; Serizawa I; Koge H; Kano K; Shima S; Tsuchida K; Mizoguchi N; Yoshida D; Katoh H; Hiruma T; Kamada T
Anticancer Res; 2022 Jul; 42(7):3701-3706. PubMed ID: 35790269
[TBL] [Abstract] [Full Text] [Related]
15. clinical course of Coronavirus Disease-19 in patients with haematological malignancies is characterized by a longer time to respiratory deterioration compared to non-haematological ones: results from a case-control study.
Oliva A; Curtolo A; Volpicelli L; Cancelli F; Borrazzo C; Cogliati Dezza F; Marcelli G; Gavaruzzi F; Di Bari S; Ricci P; Turriziani O; Mastroianni CM; Venditti M
Infection; 2022 Oct; 50(5):1373-1382. PubMed ID: 35781785
[TBL] [Abstract] [Full Text] [Related]
16. Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.
Tanaka N; Mori S; Kiyotani K; Ota Y; Gotoh O; Kusumoto S; Nakano N; Suehiro Y; Ito A; Choi I; Ohtsuka E; Hidaka M; Nosaka K; Yoshimitsu M; Imaizumi Y; Iida S; Utsunomiya A; Noda T; Nishikawa H; Ueda R; Ishida T
Haematologica; 2022 Oct; 107(10):2418-2431. PubMed ID: 35417939
[TBL] [Abstract] [Full Text] [Related]
17. clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.
Mukherjee A; Milton DR; Jabbour EJ; Gulbis AM; Kadia T; Jain N; Ledesma C; Burger J; Ferrajoli A; Wierda W; Medeiros LJ; Kantarjian H; Champlin R; Khouri IF
Leuk Lymphoma; 2022 Apr; 63(4):885-893. PubMed ID: 35225133
[TBL] [Abstract] [Full Text] [Related]
18. KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials.
Kaddu-Mulindwa D; Altmann B; Robrecht S; Ziepert M; Regitz E; Tausch E; Held G; Poeschel V; Lesan V; Bittenbring JT; Thurner L; Pfreundschuh M; Christofyllakis K; Truemper L; Loeffler M; Schmitz N; Hoth M; Hallek M; Fischer K; Stilgenbauer S; Bewarder M; Rixecker TM
Lancet Haematol; 2022 Feb; 9(2):e133-e142. PubMed ID: 35114151
[TBL] [Abstract] [Full Text] [Related]
19. Long-Term clinical outcomes and Sequelae of Therapy in Early-Stage Orbital Mucosa-Associated Lymphoid Tissue lymphoma.
Panda G; Kalra B; Rishi A; Khanna N; Kakoti S; Sridhar E; Shet T; Sengar M; Nayak L; Bagal B; Jain H; Laskar SS; Goda JS
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):513-522. PubMed ID: 35027338
[TBL] [Abstract] [Full Text] [Related]
20. HELICOBACTER PYLORI cagA VIRULENCE GENE AND SEVERE ESOGASTRODUODENAL DISEASES: IS THERE AN ASSOCIATION?
Oliveira AKS; Silva LLL; Miguel MP; Blanco AJV; Carneiro LC; Barbosa MS
Arq Gastroenterol; 2021; 58(4):468-475. PubMed ID: 34909852
[TBL] [Abstract] [Full Text] [Related]
[Next]
